NASDAQ: VERVVerve Therapeutics Inc Stock
$5.67+0.21 (+3.85%)
Updated Apr 30, 2025
VERV Price
$5.67
Fair Value Price
N/A
Market Cap
$503.47M
52 Week Low
$2.87
52 Week High
$9.31
P/E
-2.41x
P/B
1.02x
P/S
14.78x
PEG
N/A
Dividend Yield
N/A
Revenue
$32.33M
Earnings
-$198.71M
Gross Margin
100%
Operating Margin
-613.51%
Profit Margin
-614.6%
Debt to Equity
0.31
Operating Cash Flow
-$158M
Beta
1.99
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VERV Overview
Verve Therapeutics Incorporated developing a novel approach to the care of cardiovascular disease - transforming treatment from chronic management to single-course gene editing medicines. Verve's lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient's risk for cardiovascular disease. Verve Therapeutics was incorporated in 2018 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VERV's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VERV
Ranked#251 of 462
Ranked#251 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important VERV news, forecast changes, insider trades & much more!
VERV News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VERV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VERV is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VERV is good value based on its book value relative to its share price (1.02x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
VERV is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VERV due diligence checks available for Premium users.
Valuation
VERV fair value
Fair Value of VERV stock based on Discounted Cash Flow (DCF)
Price
$5.67
Fair Value
$1.52
Overvalued by
272.92%
VERV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VERV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.41x
Industry
-162.28x
Market
29.18x
VERV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.02x
Industry
4.45x
VERV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VERV's financial health
Profit margin
Revenue
$13.1M
Net Income
-$50.0M
Profit Margin
-382.5%
VERV's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VERV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$647.4M
Liabilities
$154.0M
Debt to equity
0.31
VERV's short-term assets ($542.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VERV's short-term assets ($542.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VERV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VERV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$40.8M
Investing
$29.5M
Financing
$25.2M
VERV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VERV vs Biotech Stocks
Verve Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.